Pluri Inc. (NASDAQ:PLUR) Short Interest Down 31.4% in February

Pluri Inc. (NASDAQ:PLUR) was the recipient of a significant drop in short interest in February. As of February 15th, there was short interest totalling 30,000 shares, a drop of 31.4% from the January 31st total of 43,700 shares. Based on an average daily volume of 16,400 shares, the short-interest ratio is currently 1.8 days. Approximately 0.6% of the company’s stock are short sold.

Pluri Price Performance

NASDAQ PLUR opened at $4.44 on Wednesday. The company has a debt-to-equity ratio of 4.44, a quick ratio of 5.04 and a current ratio of 5.04. The firm’s 50 day moving average price is $4.42 and its 200-day moving average price is $4.86. Pluri has a 52-week low of $4.07 and a 52-week high of $8.48. The company has a market cap of $31.07 million, a PE ratio of -0.79 and a beta of 1.67.

Pluri (NASDAQ:PLUR) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.53) earnings per share (EPS) for the quarter. Pluri had a negative net margin of 3,551.49% and a negative return on equity of 2,778.13%.

Hedge Funds Weigh In On Pluri

An institutional investor recently raised its position in Pluri stock. Renaissance Technologies LLC increased its holdings in shares of Pluri Inc. (NASDAQ:PLUR) by 38.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 34,025 shares of the company’s stock after purchasing an additional 9,400 shares during the period. Renaissance Technologies LLC owned 0.61% of Pluri worth $145,000 as of its most recent SEC filing. 16.59% of the stock is currently owned by institutional investors.

Pluri Company Profile

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.